Status:
COMPLETED
Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents
Lead Sponsor:
Novartis Vaccines
Collaborating Sponsors:
Novartis
Conditions:
Prevention of Meningococcal Disease
Eligibility:
All Genders
11-17 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in comparison to licensed meningococcal polysaccharide vaccine administered to h...
Eligibility Criteria
Inclusion
- Healthy adolescents between and including 11-17 years of age, who provide written informed consent
Exclusion
- Subjects with a previous or suspected disease caused by N. meningitidis; or previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s); Any serious acute, chronic or progressive disease
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2006
Estimated Enrollment :
524 Patients enrolled
Trial Details
Trial ID
NCT00262041
Start Date
October 1 2004
End Date
March 1 2006
Last Update
June 28 2018
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Rochester, Minnesota, United States, 55905
2
Pittsburgh, Pennsylvania, United States, 15241
3
Seattle, Washington, United States, 98101